---
title: "Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Economic information and modeling report"
description: "Formulary evidence on Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Economic information and modeling report. Covers Cost-effectiveness evidence. 37 evidence topics quoted from 29 sources."
canonical: "https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics/cost-effectiveness"
published: "2026-11-18T22:34:49-05:00"
modified: "2026-11-18T22:34:49-05:00"
---

# Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Economic information and modeling report

<a id="economic-information-and-modeling-report"></a>

## 4 Economic Information and Modeling Report

<a id="heading-4.1"></a>

### 4.1 Modeling Overview

<a id="topic-4.1-1"></a>

#### Summary: comparator prices, payer criteria, ICER assessment, published economic evaluations, and utility weights

No price, cost-effectiveness analysis, or budget impact analysis of lanifibranor was identified. Inventiva states that market acceptance of lanifibranor “will depend significantly on the availability of coverage and adequate reimbursement from third-party payors”.

The two approved comparators for noncirrhotic MASH with F2 to F3 fibrosis have these published prices. Resmetirom (Rezdiffra) has a wholesale acquisition cost of $4,239.38 per 30-tablet package for each strength (60, 80, and 100 mg) as of October 1, 2026, and was reported at a launch annual wholesale acquisition cost of $47,400 in March 2024. Semaglutide 2.4 mg (Wegovy) has a list price of $1,349.02 per package; Novo Nordisk announced on February 24, 2026 that the list price of Wegovy will be lowered to $675, effective January 1, 2027, a reduction of approximately 50%.

Five payer policies were reviewed (Cigna, Prime Therapeutics HCSC, Aetna, PA Health and Wellness, Alaska Medicaid). Each requires F2 or F3 fibrosis confirmed by liver biopsy or noninvasive testing, with biopsy look-back periods of 12 months to 3 years where one is stated, and Cigna, Aetna, and PA Health and Wellness require prescribing by or in consultation with a specialist. Prime Therapeutics HCSC requires an inadequate response after 72 weeks of semaglutide, or one of its listed exceptions, before resmetirom, and PA Health and Wellness requires a 6-month semaglutide trial in members without F3 fibrosis. ICER's 2023 policy recommendations state that liver biopsy should not be universally required for diagnosis and that step therapy requiring prior pioglitazone or vitamin E is not reasonable.

ICER's May 2023 assessment rated resmetirom “C++” compared with standard of care in NASH with F2 or F3 fibrosis. Its lifetime Markov model (health care sector perspective, annual cycles) used utilities of 0.76 for fibrosis stages F0 to F2 and 0.73 for F3, derived from the GAIN study, and annual costs of $7,063 and $8,423 for those states, based on US estimates from the GAIN study (2022 US dollars). At a placeholder price of $19,000 per year, resmetirom produced lifetime savings of approximately $22,400 and approximately 0.60 QALYs gained. The health-benefit price benchmark for resmetirom was $39,600 to $50,100. ICER applied a prevalence of 1.4% to US adults, assumed 762,119 treatment initiators per year, found that 6.5% of eligible patients could be treated at the placeholder price before reaching its budget impact threshold of approximately $777 million per year, and issued an access and affordability alert.

Published US cost-effectiveness analyses of the approved comparators report these incremental cost-effectiveness ratios (the first three against standard of care): semaglutide $42,200 and resmetirom $95,981 per QALY at 5 years (US payer perspective); semaglutide 2.4 mg $19,911, resmetirom 80 mg $346,810, and resmetirom 100 mg $198,607 per QALY over a lifetime (model developed under contract with Novo Nordisk); tirzepatide $42,705, semaglutide $80,076, and resmetirom $273,445 per QALY over a lifetime, using annual treatment costs of $59,268.96 for resmetirom and $16,188.24 for semaglutide; and resmetirom $53,929 per QALY in an early Madrigal-funded analysis. A cost-utility analysis of pioglitazone and vitamin E in NASH with fibrosis level 3 or greater reported $A2748 and $A8475 per QALY gained compared with lifestyle modification alone. Noninvasive-test screening strategies for high-risk MASLD in US primary care, with resmetirom treatment of F2 or F3 fibrosis in the model, ranged from $23,265 to $27,884 per QALY.

A Madrigal-funded budget impact analysis for a hypothetical one-million-member US private plan estimated 50 to 238 patients treated with resmetirom over years 1 to 3, a net budget impact of $2.2 to $9.5 million, and $0.19 to $0.80 per member per month. A Madrigal-funded calculator estimated 1,255 to 1,699 treatment-eligible adults per 1 million commercial members in years 1 to 3, and an NHANES 2017 to March 2020 analysis estimated 8.3 million (liberal criteria) and 2.3 million (restrictive criteria) US adults meeting resmetirom eligibility criteria.

Published utility weights by fibrosis stage include mean EQ-5D indices of 0.80 (F0 to F2) and 0.67 (F3 to F4) in US respondents of the GAIN study, discrete choice experiment-derived values of 0.671 (MASH F2) and 0.605 (MASH F3) used as model inputs, and a mapped EQ-5D utility of approximately 0.78 at baseline in ESSENCE.

Source: [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm); [Madrigal Pharmaceuticals Colorado price disclosure (2026)](https://www.madrigalpharma.com/wp-content/uploads/2026/10/Resmetirom-Price-Transparency-by-State-Form-Colorado-Oct-2026.pdf); [Joszt (2024)](https://www.ajmc.com/view/fda-approves-resmetirom-first-treatment-for-nash-with-liver-fibrosis); [NovoCare MASH list price (2025)](https://www.novocare.com/mash/resources/explaining-list-price.html); [Novo Nordisk (2026)](https://www.novonordisk-us.com/media/news-archive/news-details.html?id=916505); [Cigna Rezdiffra prior authorization policy (2026)](https://a.static.cigna.com/assets/chcp/pdf/coveragePolicies/cnf/cnf_852_coveragepositioncriteria_hepatology_rezdiffra_pa.pdf); [Prime Therapeutics HCSC resmetirom program summary (2026)](https://www.myprime.com/content/dam/prime/memberportal/forms/AuthorForms/HCSC/Program_Summaries/HCSC_Resmetirom_PAQL_ProgSum.pdf); [Aetna Wegovy precertification policy (2026)](https://www.aetna.com/products/rxnonmedicare/data/2026/Wegovy%20PA%20with%20Limit%204774-C%2008-2026%20v2.html); [PA Health and Wellness resmetirom clinical policy (2025)](https://www.pahealthwellness.com/content/dam/centene/Pennsylvania/policies/pharmacy-policies/Resmetirom_Rezdiffra_v1.2025.pdf); [Alaska Medicaid Rezdiffra criteria (2026)](https://health.alaska.gov/media/p0fbdtwy/rezdiffra_criteria_2026.pdf); [ICER Final Policy Recommendations, NASH (2023)](https://icer.org/wp-content/uploads/2023/05/NASH_Policy-Recs_Final.pdf); [ICER Final Evidence Report, resmetirom and obeticholic acid for NASH (2023)](https://icer.org/wp-content/uploads/2025/01/NASH-Final-Report_Updated_011025.pdf); [Njei et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13126990/); [McGovern et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13694306/); [Abdeen et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13449014/); [Javanbakht et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9929016/); [Mahady et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22707355/); [Younossi et al. (2025a)](https://pubmed.ncbi.nlm.nih.gov/39373093/); [Fishman et al. (2024a)](https://www.tandfonline.com/doi/full/10.1080/13696998.2024.2393952); [Fishman et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11480167/); [Le et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12180822/); [O'Hara et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7397699/); [Aggio et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10842270/); [Augusto et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13651485/)

<a id="topic-4.1-2"></a>

#### Resmetirom (Rezdiffra) wholesale acquisition cost per 30-tablet package, October 2026

| Marketed product | WAC package | Package size |
| --- | --- | --- |
| Rezdiffra 60 mg | “$4,239.38” | “30” |
| Rezdiffra 80 mg | “$4,239.38” | “30” |
| Rezdiffra 100 mg | “$4,239.38” | “30” |

Source: [Madrigal Pharmaceuticals Colorado price disclosure (2026)](https://www.madrigalpharma.com/wp-content/uploads/2026/10/Resmetirom-Price-Transparency-by-State-Form-Colorado-Oct-2026.pdf)

> “The information is accurate as of 10/01/2026.”
> “The prices listed are WAC prices, which represent Madrigal Pharmaceuticals, Inc.’s published list prices for the products sold to wholesalers, before any discount, rebate, or other price reduction.”

Source: [Madrigal Pharmaceuticals Colorado price disclosure (2026)](https://www.madrigalpharma.com/wp-content/uploads/2026/10/Resmetirom-Price-Transparency-by-State-Form-Colorado-Oct-2026.pdf)

<a id="topic-4.1-3"></a>

#### Resmetirom annual wholesale acquisition cost at launch, March 2024, superseded by January 2026

> “March 14, 2024”
> “The FDA has granted accelerated approval to resmetirom (Rezdiffra; Madrigal Pharmaceuticals)”
> “The company priced the drug with an annual wholesale acquisition cost of $47,400”

Source: [Joszt (2024)](https://www.ajmc.com/view/fda-approves-resmetirom-first-treatment-for-nash-with-liver-fibrosis)

> “The information is accurate as of 01/01/2026.”
> “$4,239.38”

Source: [Madrigal Pharmaceuticals Connecticut price disclosure, January 2026 (2026)](https://www.madrigalpharma.com/wp-content/uploads/2026/02/Resmetirom-Price-Transparency-by-State-Form-Connecticut-Jan-2026.pdf)

<a id="topic-4.1-4"></a>

#### Semaglutide 2.4 mg (Wegovy) list price per package

> “List price is the original price set for a medication by a manufacturer before any discounts or rebates are applied.”
> “Wegovy® has a list price of $1,349.02/package”

Source: [NovoCare MASH list price (2025)](https://www.novocare.com/mash/resources/explaining-list-price.html)

<a id="topic-4.1-5"></a>

#### Semaglutide (Wegovy) list price of $675 per month scheduled for January 2027, announced February 2026

> “Feb. 24, 2026 /PRNewswire/ --Today, Novo Nordisk announced that, effective January 1, 2027, the company will lower the list price, or wholesale acquisition cost (WAC), of Wegovy® (semaglutide) injection 2.4 mg and tablets 25 mg”
> “to $675, representing reductions of approximately 50% and 35% for Wegovy® and Ozempic®, respectively, from the current list price.”
> “This decision applies to all doses of these medicines”
> “These changes in list price do not have an impact on direct-to-patient, self-pay prices”

Source: [Novo Nordisk (2026)](https://www.novonordisk-us.com/media/news-archive/news-details.html?id=916505)

<a id="topic-4.1-6"></a>

#### Payer coverage: Cigna National Formulary prior authorization criteria for resmetirom, April 2026

> “Cigna National Formulary Coverage”
> “REVIEW DATE: 04/08/2026”
> “Prior Authorization is recommended for prescription benefit coverage of Rezdiffra.”
> “Approve for 1 year if the patient meets ONE of the following (A or B):”
> “Patient has stage F2 or F3 fibrosis prior to initiating treatment with Rezdiffra, Wegovy injection, Wegovy HD injection, or Wegovy tablet”
> “Liver biopsy performed within the 3 years preceding treatment with Rezdiffra, Wegovy injection, Wegovy HD injection, or Wegovy tablet”
> “Vibration-controlled transient elastography (VCTE) performed within the 6 months preceding treatment with Rezdiffra, Wegovy injection, Wegovy HD injection, or Wegovy tablet”
> “with a score of ≥ 9.2 to ≤ 10.5”
> “The medication is prescribed by or in consultation with an endocrinologist, gastroenterologist, or hepatologist”
> “Patient has completed ≥ 1 year of therapy with Rezdiffra AND according to the prescriber, the patient has not had worsening of fibrosis or MASH/NASH”

Source: [Cigna Rezdiffra prior authorization policy (2026)](https://a.static.cigna.com/assets/chcp/pdf/coveragePolicies/cnf/cnf_852_coveragepositioncriteria_hepatology_rezdiffra_pa.pdf)

<a id="topic-4.1-7"></a>

#### Payer coverage: Prime Therapeutics HCSC resmetirom criteria with a semaglutide (Wegovy) step, November 2026

> “11-01-2026”
> “The patient has stage F2 or F3 fibrosis as confirmed by ONE of the following (prior to therapy with the requested agent):”
> “A liver biopsy within the past 2 years OR”
> “Enhanced liver fibrosis (ELF) score of 9.2 to 11.2 OR”
> “The patient has tried and had an inadequate response after 72 weeks of therapy with Wegovy injection”
> “The patient has an intolerance or hypersensitivity to therapy with Wegovy injection”

Source: [Prime Therapeutics HCSC resmetirom program summary (2026)](https://www.myprime.com/content/dam/prime/memberportal/forms/AuthorForms/HCSC/Program_Summaries/HCSC_Resmetirom_PAQL_ProgSum.pdf)

<a id="topic-4.1-8"></a>

#### Payer coverage: Aetna non-Medicare prior authorization criteria for semaglutide (Wegovy injection) in noncirrhotic MASH, August 2026 policy

> “Aetna Non-Medicare Prescription Drug Plan”
> “Wegovy PA with Limit 4774-C 08-2026 v2”
> “Noncirrhotic Metabolic Dysfunction-Associated Steatohepatitis (Adult) – Wegovy Injection ONLY (EXCLUDING Wegovy HD 7.2 mg Injection)”
> “The requested drug is being prescribed by, or in consultation with, a gastroenterologist or hepatologist.”
> “The patient’s moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) at baseline has been confirmed by ONE of the following: non-invasive liver disease assessment (e.g., ultrasound-based elastography, magnetic resonance elastography [MRE], enhanced liver fibrosis [ELF] score) OR historical liver biopsy.”
> “Noncirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH): DOA: 12 months”

Source: [Aetna Wegovy precertification policy (2026)](https://www.aetna.com/products/rxnonmedicare/data/2026/Wegovy%20PA%20with%20Limit%204774-C%2008-2026%20v2.html)

<a id="topic-4.1-9"></a>

#### Payer coverage: PA Health and Wellness resmetirom criteria requiring a semaglutide (Wegovy) trial in members without F3 fibrosis, October 2025

> “Revision Date:  10/2025”
> “Prescribed by or in consultation with a hepatologist or gastroenterologist;”
> “Liver biopsy within the last 3 years;”
> “For member without advanced fibrosis (F3): Failure of a ≥ 6-month trial of Wegovy®, unless contraindicated or clinically significant adverse effects are experienced;”
> “Rezdiffra is not prescribed concurrently with Wegovy;”
> “Approval duration: 12 months”

Source: [PA Health and Wellness resmetirom clinical policy (2025)](https://www.pahealthwellness.com/content/dam/centene/Pennsylvania/policies/pharmacy-policies/Resmetirom_Rezdiffra_v1.2025.pdf)

<a id="topic-4.1-10"></a>

#### Payer coverage: Alaska Medicaid prior authorization criteria for resmetirom, effective June 2026

> “ALASKA MEDICAID”
> “Effective: 6/1/2026”
> “Patient has liver fibrosis stage F2 or F3, confirmed by liver biopsy within the previous 12 months or two or more of the following:”
> “Magnetic resonance elastography (MRE) score >2.6”
> “Vibration-controlled transient elastography (VCTE) score >8.1”
> “Enhanced liver fibrosis (ELF) score >7.7 AND;”
> “Patient Fibrosis 4 index (FIB-4) score ≥ 1.3 AND;”
> “Initial Approval: up to 3 months”
> “Reauthorization: up to 12 months”

Source: [Alaska Medicaid Rezdiffra criteria (2026)](https://health.alaska.gov/media/p0fbdtwy/rezdiffra_criteria_2026.pdf)

<a id="topic-4.1-11"></a>

#### ICER coverage policy recommendations for NASH therapies, May 2023

> “Final Policy Recommendations”
> “May 25, 2023”
> “it will be reasonable for payers to use prior authorization as a component of coverage for NASH therapies.”
> “For NASH, both price-volume and outcomes-based agreements may be considered to manage the uncertainties surrounding the annual costs for these drugs.”
> “liver biopsy should not be universally required for diagnosis.”
> “Clinical eligibility: Patients eligible for therapy will include all patients with stage F2 or F3 fibrosis.”
> “Step therapy requiring prior treatment with pioglitazone and/or vitamin E is not reasonable.”
> “It is reasonable to limit prescribing to hepatologists or gastroenterologists until more is known about safety and efficacy in real world use.”
> “Since stabilization of fibrosis can demonstrate clinical benefit for some patients, resolution of NASH or improvement in fibrosis should be not required for continuation of coverage.”

Source: [ICER Final Policy Recommendations, NASH (2023)](https://icer.org/wp-content/uploads/2023/05/NASH_Policy-Recs_Final.pdf)

<a id="topic-4.1-12"></a>

#### ICER evidence rating for resmetirom compared with standard of care, May 2023

> “Final Evidence Report”
> “May 25, 2023”
> “As such, for resmetirom we conclude that in NASH with F2 or F3 fibrosis there is moderate certainty of comparable to substantial net health benefits with high certainty of at least comparable benefits compared with standard of care (C++).”

Source: [ICER Final Evidence Report, resmetirom and obeticholic acid for NASH (2023)](https://icer.org/wp-content/uploads/2025/01/NASH-Final-Report_Updated_011025.pdf)

<a id="topic-4.1-13"></a>

#### ICER cost-effectiveness model: structure, perspective, and time horizon

> “The base-case analysis takes a health care sector perspective (i.e., focuses on direct medical care costs only), and a lifetime horizon.”
> “Model cycle length was annual.”
> “The Markov model structure was composed of two cardiovascular (CV) event history submodels with equivalent liver disease-specific state transition probabilities”
> “Each submodel allows for transitions among no fibrosis (F0) and discrete fibrosis (F1-F3) stages, compensated cirrhosis (F4), decompensated cirrhosis, hepatocellular carcinoma (HCC), post-liver transplant, and death.”
> “Diabetes was not explicitly modeled due to lack of data on differential effects by diabetes status.”

Source: [ICER Final Evidence Report, resmetirom and obeticholic acid for NASH (2023)](https://icer.org/wp-content/uploads/2025/01/NASH-Final-Report_Updated_011025.pdf)

<a id="topic-4.1-14"></a>

#### ICER cost-effectiveness model: health-state utilities by fibrosis stage

> “Health state utilities were derived from the Global Assessment of the Impact of NASH (GAIN) study”
> “Cirrhosis and HCC utilities were obtained from patients with hepatitis C”

Source: [ICER Final Evidence Report, resmetirom and obeticholic acid for NASH (2023)](https://icer.org/wp-content/uploads/2025/01/NASH-Final-Report_Updated_011025.pdf)

| Health state | Base case | Lower value | Upper value |
| --- | --- | --- | --- |
| NASH fibrosis stage 0 to 2 | “0.76” | “0.61” | “0.91” |
| NASH fibrosis stage 3 | “0.73” | “0.64” | “0.82” |
| Compensated cirrhosis | “0.66” | “0.49” | “0.83” |
| Decompensated cirrhosis | “0.57” | “0.46” | “0.68” |
| Hepatocellular carcinoma | “0.50” | “0.40” | “0.60” |
| Liver transplantation (year of) | “0.66” | “0.49” | “0.83” |
| Post-liver transplantation | “0.73” | “0.64” | “0.82” |
| Disutility: myocardial infarction event | “-0.041” | “-0.041” | “-0.041” |
| Disutility: stroke event | “-0.052” | “-0.053” | “-0.052” |

Source: [ICER Final Evidence Report, resmetirom and obeticholic acid for NASH (2023)](https://icer.org/wp-content/uploads/2025/01/NASH-Final-Report_Updated_011025.pdf)

<a id="topic-4.1-15"></a>

#### ICER cost-effectiveness model: annual non-drug costs by health state, 2022 US dollars

> “All costs used in the model were updated to 2022 US dollars.”
> “We used NASH-specific costs for early and advanced fibrosis based on the US estimates from the GAIN study”

Source: [ICER Final Evidence Report, resmetirom and obeticholic acid for NASH (2023)](https://icer.org/wp-content/uploads/2025/01/NASH-Final-Report_Updated_011025.pdf)

| Health state | Base case | Lower value | Upper value |
| --- | --- | --- | --- |
| F0 to F2 | “$7,063” | “$5,650” | “$8,475” |
| F3 | “$8,423” | “$6,738” | “$10,108” |
| Compensated cirrhosis | “$34,275” | “$27,420” | “$41,131” |
| Decompensated cirrhosis | “$158,480” | “$126,784” | “$190,176” |
| Hepatocellular carcinoma | “$115,002” | “$92,001” | “$138,002” |
| Liver transplant procedure | “$232,674” | “$186,140” | “$279,209” |
| Post liver transplant procedure | “$43,358” | “$34,686” | “$52,030” |

Source: [ICER Final Evidence Report, resmetirom and obeticholic acid for NASH (2023)](https://icer.org/wp-content/uploads/2025/01/NASH-Final-Report_Updated_011025.pdf)

<a id="topic-4.1-16"></a>

#### ICER cost-effectiveness model: resmetirom placeholder price

> “annual placeholder price of $19,000 based on a prior early economic model developed by the manufacturer.”
> “However, no rationale was given to the placeholder price and the manufacturer did not provide additional data on the price upon request.”

Source: [ICER Final Evidence Report, resmetirom and obeticholic acid for NASH (2023)](https://icer.org/wp-content/uploads/2025/01/NASH-Final-Report_Updated_011025.pdf)

<a id="topic-4.1-17"></a>

#### ICER cost-effectiveness model: base-case results for resmetirom at the placeholder price, health care sector perspective

> “Over a lifetime horizon, treatment with resmetirom resulted in incremental cost savings of approximately $22,400, and incremental QALYs and evLYs of approximately 0.60 and 0.68, respectively, compared to SC alone from the health care sector perspective.”
> “The cost-effectiveness of both drugs will depend on their price though, notably, at our placeholder price, resmetirom would appear to be cost saving.”

Source: [ICER Final Evidence Report, resmetirom and obeticholic acid for NASH (2023)](https://icer.org/wp-content/uploads/2025/01/NASH-Final-Report_Updated_011025.pdf)

| Treatment | Drug cost | Total cost | QALYs | evLYs | Life years |
| --- | --- | --- | --- | --- | --- |
| Resmetirom (placeholder price) | “$76,000” | “$416,000” | “10.66” | “10.74” | “15.05” |
| Standard care | “$0” | “$439,000” | “10.05” | “10.05” | “14.56” |

Source: [ICER Final Evidence Report, resmetirom and obeticholic acid for NASH (2023)](https://icer.org/wp-content/uploads/2025/01/NASH-Final-Report_Updated_011025.pdf)

<a id="topic-4.1-18"></a>

#### ICER threshold prices and health-benefit price benchmark for resmetirom

| Annual price to achieve | $50,000 per QALY gained | $100,000 per QALY gained | $150,000 per QALY gained | $200,000 per QALY gained |
| --- | --- | --- | --- | --- |
| Resmetirom | “$32,100” | “$39,600” | “$47,100” | “$54,600” |

Source: [ICER Final Evidence Report, resmetirom and obeticholic acid for NASH (2023)](https://icer.org/wp-content/uploads/2025/01/NASH-Final-Report_Updated_011025.pdf)

> “ICER’s Health Benefit Price Benchmark (HBPB) for resmetirom is $39,600 to $50,100 and the HBPB for OCA is $32,600 to $40,400.”

Source: [ICER Final Evidence Report, resmetirom and obeticholic acid for NASH (2023)](https://icer.org/wp-content/uploads/2025/01/NASH-Final-Report_Updated_011025.pdf)

<a id="topic-4.1-19"></a>

#### ICER potential budget impact: eligible US adults, uptake, and access and affordability alert

> “To estimate the size of the potential candidate populations for treatment, we applied a prevalence estimate of 1.4% to the 2023-2027 projected US population aged 18 years of age and older.”
> “Our estimate was based on a 4% prevalence of NASH in the overall US population [based on a reported average of 1.5% to 6.5%]”
> “For the purposes of this analysis, we assumed that 20% of these patients would initiate treatment in each of the five years, or 762,119 patients per year.”
> “The five-year annualized potential budget impact threshold that should trigger policy actions to manage access and affordability is calculated to be approximately $777 million per year for new drugs.”
> “Assuming a 20% uptake of resmetirom each year (for 50% of eligible patients given that we are assessing two new market entrants), 6.5% of patients could be treated over five years at the placeholder price before reaching the ICER potential budget impact threshold of $777 million per year.”
> “Thus, ICER is issuing an access and affordability alert.”

Source: [ICER Final Evidence Report, resmetirom and obeticholic acid for NASH (2023)](https://icer.org/wp-content/uploads/2025/01/NASH-Final-Report_Updated_011025.pdf)

<a id="topic-4.1-20"></a>

#### ICER report status: 18-month stakeholder request, January 2025

> “ICER reached out to key stakeholders included in this review 18 months after the publication of this report giving them an opportunity to submit public comments regarding new relevant data or information on coverage that they wish to highlight.”

Source: [ICER Final Evidence Report, resmetirom and obeticholic acid for NASH (2023)](https://icer.org/wp-content/uploads/2025/01/NASH-Final-Report_Updated_011025.pdf)

<a id="topic-4.1-21"></a>

#### Published cost-effectiveness analysis: semaglutide and resmetirom compared with standard of care in MASH with F2 to F3 fibrosis, US payer perspective, 5- and 10-year horizons

> “A state-transition model simulated disease progression in a hypothetical cohort with F2–F3 fibrosis over 5- and 10-year horizons from a U.S. healthcare payer perspective.”
> “Semaglutide was cost-effective versus SOC at 5 years (ICER, $42,200/QALY) and 10 years (ICER, $44,138/QALY).”
> “Resmetirom produced higher ICERs ($95,981/QALY at 5 years; $107,002/QALY at 10 years) but remained below a $150,000/QALY threshold.”
> “Over a 10-year horizon, treatment of 100,000 patients with F2–F3 MASH was projected to prevent 270 cases of decompensated cirrhosis, 10 cases of hepatocellular carcinoma, and 1,040 liver-related deaths with semaglutide, compared with 310 cases of decompensated cirrhosis, 10 cases of hepatocellular carcinoma, and 1,180 liver-related deaths with Resmetirom.”

Source: [Njei et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13126990/)

<a id="topic-4.1-22"></a>

#### Published cost-effectiveness analysis: semaglutide 2.4 mg and resmetirom compared with standard of care, US third-party payer perspective, lifetime horizon, Novo Nordisk-funded

> “Cost effectiveness was assessed from a United States (US) third-party payer perspective. The impact of semaglutide 2.4 mg on quality-adjusted life years (QALYs), cost, and clinical outcomes was simulated over a lifetime horizon.”
> “Costs were adjusted to 2025 US dollars. Costs and health outcomes were discounted at 3% annually.”
> “In the cost-effectiveness analysis, semaglutide 2.4 mg had an incremental cost-effectiveness ratio of US$19,911 per QALY gained compared with SoC, while corresponding incremental cost-effectiveness ratios were US$346,810 for resmetirom 80 mg and US$198,607 for resmetirom 100 mg.”
> “In a scenario analysis that used the direct-to-consumer cash price for semaglutide 2.4 mg (US$499 per month), semaglutide 2.4 mg was less costly and more effective than SoC.”
> “These utilities were taken from the Institute for Clinical and Economic Review 2023 NASH assessment, which sourced fibrosis stage values from the GAIN study”
> “FC is an employee of Genesis Research Group (Hoboken, NJ), which was contracted by Novo Nordisk Inc., Plainsboro, NJ, USA to develop the model and manuscript.”

Source: [McGovern et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13694306/)

<a id="topic-4.1-23"></a>

#### Published cost-effectiveness analysis: resmetirom, semaglutide, and tirzepatide compared with standard of care in MASH with F2 to F3 fibrosis, US payer perspective, lifetime horizon, with model inputs

> “We evaluated the cost-effectiveness of resmetirom, semaglutide and tirzepatide for U.S. adults with MASH and F2-F3 fibrosis.”
> “We developed a Markov cohort model with a lifetime horizon from the perspective of a U.S. healthcare payer.”
> “In the base-case analysis, tirzepatide had the largest QALY gain and the lowest incremental cost relative to standard of care, yielding an incremental cost-effectiveness ratio of ($42 705/QALY). Semaglutide was also cost-effective (ICER: $80 076/QALY). Resmetirom (ICER: $273 445/QALY) exceeded the WTP threshold.”
> “Drug price was the most influential parameter in sensitivity analyses”

Source: [Abdeen et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13449014/)

> “All drug prices used in the model reflect wholesale acquisition cost (WAC) values as listed by the manufacturers.”
> “Stage‐specific utilities for MASH and fibrosis F1 through decompensated cirrhosis were taken from a primary EQ‐5D‐5L and discrete choice experiment elicitation study”

Source: [Abdeen et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13449014/)

| Model input | Base case | Range |
| --- | --- | --- |
| Annual treatment cost ($), resmetirom | “59268.96” | “(47415.17, 71122.75)” |
| Annual treatment cost ($), semaglutide | “16188.24” | “(12950.59, 19425.89)” |
| Annual treatment cost ($), tirzepatide | “13036.44” | “(10429.15, 15643.73)” |
| Annual health state cost ($), MASH F2 | “512.94” | “(410.35, 615.53)” |
| Annual health state cost ($), MASH F3 | “631.39” | “(505.11, 757.67)” |
| Annual health state cost ($), F4 | “22501.38” | “(18001.1, 27001.66)” |
| Utility, MASH F2 | “0.671” | “(0.607, 0.736)” |
| Utility, MASH F3 | “0.605” | “(0.591, 0.620)” |
| Utility, MASH F4 | “0.500” | “(0.478, 0.523)” |
| Utility, decompensated cirrhosis | “0.251” | “(0.204, 0.299)” |

Source: [Abdeen et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13449014/)

<a id="topic-4.1-24"></a>

#### Published early cost-effectiveness analysis of resmetirom, US commercial payer perspective, Madrigal-funded

> “This early analysis explored the potential cost effectiveness of resmetirom for the treatment of NASH from a US commercial payer perspective.”
> “Resmetirom treatment resulted in increased costs of US$66,764 per patient, while increasing QALYs by 1.24. The incremental cost-effectiveness ratio was US$53,929 per QALY gained”
> “Resmetirom treatment remained cost effective at a US$100,000 WTP threshold up to a daily price point of US$72.00.”
> “This research was funded by Madrigal Pharmaceuticals, Inc.”

Source: [Javanbakht et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9929016/)

| Model input | Base-case value |
| --- | --- |
| Cost of resmetirom, oral, 100 mg daily (US$) | “U.S.$52.05” |

Source: [Javanbakht et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9929016/)

<a id="topic-4.1-25"></a>

#### Published cost-utility analysis: pioglitazone and vitamin E in biopsy-proven NASH with fibrosis level 3 or greater, third-party payer perspective, costs in Australian dollars ($A)

> “Using a third-party payer perspective, a deterministic Markov model was developed to compare costs and health benefits of lifestyle modification alone or with pioglitazone or vitamin E in a cohort of patients aged 50 years with biopsy-proven NASH and fibrosis level 3 or greater.”
> “In comparison with lifestyle modification alone, treatment with either pioglitazone or vitamin E in addition to lifestyle modification was cost-effective, with incremental cost-effectiveness ratios of $A2748 and $A8475 per quality-adjusted life year (QALY) gained, respectively.”

Source: [Mahady et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22707355/)

<a id="topic-4.1-26"></a>

#### Published cost-utility analysis: noninvasive-test screening strategies for high-risk MASLD in US primary care, including resmetirom treatment of F2 or F3 fibrosis

> “All screening strategies for high-risk MASLD in US incurred additional costs compared to no screening”
> “The model included treatment effects of resmetirom for metabolic dysfunction-associated steatohepatitis (MASH) patients with F2 or F3 fibrosis.”
> “ICERs ranged from $26 913 to $27 884 per QALY for T2D patients and $23 265 to $24  992 per QALY for patients with obesity.”

Source: [Younossi et al. (2025a)](https://pubmed.ncbi.nlm.nih.gov/39373093/)

<a id="topic-4.1-27"></a>

#### Published generalized cost-effectiveness analysis: screening and treatment of MASH in people with type 2 diabetes, 12 countries including the United States

> “This economic evaluation consisted of a generalized cost-effectiveness analysis (GCEA) that was conducted for 12 countries (Brazil, Chile, Germany, Italy, Japan, Saudi Arabia, South Africa, Spain, Sweden, Tanzania, Thailand, and the United States), across all 6 World Health Organization (WHO) regions.”
> “Treatment with intensive lifestyle interventions (ILIs), after screening via ELF or VCTE, was cost-effective in all countries. ILIs and treatment with semaglutide was cost-effective in 11 countries (not in Tanzania); ILIs and treatment with resmetirom was cost-effective in 8 countries (not in Brazil, South Africa, Tanzania, or Thailand).”

Source: [Lazarus et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12593099/)

<a id="topic-4.1-28"></a>

#### Published US disease burden model: hypothetical therapy that halts fibrosis progression

> “The US MASLD disease burden model is a Markov model which forecasts disease progression and the impact of diagnosis and treatment.”
> “The scenarios in which a hypothetical therapy halts fibrosis progression resulted in reductions in cases of decompensated cirrhosis (11-39%), hepatocellular carcinoma (10-34%), and liver-related deaths (8-31%), a 9-31% reduction in cumulative DALYs, and $40.5 to $99.1B incremental healthcare costs averted.”

Source: [Wallace et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39832655/)

<a id="topic-4.1-29"></a>

#### Budget impact analysis: resmetirom in a hypothetical one-million-member US private health plan over 3 years, Madrigal-funded

> “A three-year budget impact analysis based on an open cohort state transition model was developed for a hypothetical one-million-member private health plan.”
> “from a US private payer perspective.”
> “The resmetirom price was based on its March 2024 wholesale acquisition cost (WAC)”
> “In the projected scenario case where resmetirom is covered in a one-million-member private payer, 50, 117, and 238 patients were treated with resmetirom in each of the first 3 years.”
> “Compared with a scenario without resmetirom, the introduction of resmetirom yielded results ranging from 50 to 238 treated patients, net budget impact of $2.2 to $9.5 million, and PMPM from $0.19 to $0.80 over years one and three.”
> “the model operated under the assumption that 4%, 8%, and 14% of treatment-eligible patients would receive resmetirom in the first three years of the projected scenario.”
> “Market shares are based on internal forecasts, a short time horizon, average treatment effects, and other limitations common to BIMs.”
> “Design, study conduct, and financial support for the study were provided by Madrigal Pharmaceuticals, Inc.”

Source: [Fishman et al. (2024a)](https://www.tandfonline.com/doi/full/10.1080/13696998.2024.2393952)

<a id="topic-4.1-30"></a>

#### Eligible population per 1 million US commercial members: diagnosed adults with noncirrhotic NASH and F2 to F3 fibrosis, Madrigal-funded calculator

> “adults with non-cirrhotic nonalcoholic steatohepatitis (NASH) with moderate-to-advanced liver fibrosis (MALF) consistent with stages F2/F3 fibrosis”
> “In the base case, a NASH prevalence of 4.6% was modeled (range 1.3-14.2%). This value was multiplied by the proportion estimated to have non-cirrhotic MALF (i.e., 35%).”
> “Published analyses suggest a diagnosis rate of ~ 10% (range 3.3-14.3%) and ~ 16% year-over-year growth in the treatment-eligible population.”
> “Assuming a 1-million commercial-member population, the resmetirom treatment-eligible population was estimated as 1255-1699 in Years 1-3 following approval.”
> “Design, study conduct, and financial support (including the journal’s Rapid Service Fee and Open Access Fee) for the study were provided by Madrigal Pharmaceuticals, Inc.”

Source: [Fishman et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11480167/)

<a id="topic-4.1-31"></a>

#### Eligible population: US adults meeting resmetirom eligibility criteria, NHANES 2017 to March 2020

> “A cross-sectional analysis was conducted using data from the National Health and Nutrition Examination Survey (NHANES) 2017-March 2020 cycle.”
> “An estimated 8.3 million (95% CI: 6.6-9.9 million) adults met the liberal eligibility criteria, while 2.3 million (95% CI: 1.4-3.2 million) met the restrictive criteria.”

Source: [Le et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12180822/)

<a id="topic-4.1-32"></a>

#### Health-state utility weights: EQ-5D by early (F0 to F2) and advanced (F3 to F4) fibrosis in biopsy-confirmed NASH, GAIN study, Europe and the United States

> “The Global Assessment of the Impact of NASH (GAIN) study is a prevalence-based burden of illness study across Europe (France, Germany, Italy, Spain, and the UK) and the USA.”
> “In total, 3,754 patients found to have NASH on liver biopsy were stratified by fibrosis score and by biomarkers as either early or advanced fibrosis.”
> “Mean EQ-5D and CLDQ-NAFLD index scores were 0.75 and 4.9, respectively.”
> “In general, there was a clear pattern of decreasing HRQoL score with worsening fibrosis score in all countries, with the exception of France, where similar scores were seen in both early and advanced fibrosis.”

Source: [O'Hara et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7397699/)

| EQ-5D index, mean (SD) | Early (F0 to F2) | Advanced (F3 to F4) | Overall |
| --- | --- | --- | --- |
| United States | “0.80 (0.19)” | “0.67 (0.23)” | “0.75 (0.22)” |
| All countries | “0.80 (0.2)” | “0.62 (0.33)” | “0.75 (0.26)” |

Source: [O'Hara et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7397699/)

<a id="topic-4.1-33"></a>

#### Health-state utility weights: EQ-5D estimated from CLDQ-NAFLD and SF-36 in noncirrhotic MASH

> “Baseline data of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) patients were used in this study.”
> “There were 883 MASH patients with CLDQ-NAFLD and SF-36 data: 25% ≥65 years, 44% male, 80% obese (body mass index >30), 67% type 2 diabetes, 62% F3 fibrosis, and 38% F1B/F2 fibrosis.”
> “The mean estimated EQ-5D scores were 0.851 (standard deviation = 0.146) according to CLDQ-NAFLD-based algorithm and 0.853 (standard deviation = 0.097) according to the SF-36-based algorithm.”

Source: [Younossi et al. (2025d)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12277723/)

<a id="topic-4.1-34"></a>

#### Health-state utility weights: discrete choice experiment by fibrosis stage, UK general public and patients with NASH, Boehringer Ingelheim-funded

> “DCE surveys were completed by the UK general public (n = 520) and patients with NASH (n = 154). The utility decline between fibrosis stages F1 and F4 decompensated was between -0.521 to -0.646 (depending on method).”
> “Financial support for this study was provided by a contract with Boehringer Ingelheim International GmbH.”

Source: [Aggio et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10842270/)

<a id="topic-4.1-35"></a>

#### Health-state utility weights: mapped EQ-5D at baseline and week 72 with semaglutide 2.4 mg in MASH with F2 or F3 fibrosis, ESSENCE, Novo Nordisk-sponsored

> “This exploratory analysis used Week 72 data from ESSENCE Part 1”
> “Adults with biopsy-confirmed MASH and fibrosis stage F2 or F3 were randomized 2:1”
> “Baseline mapped EQ-5D utility was approximately 0.78 in both groups.”
> “At Week 72, semaglutide significantly improved mapped EQ-5D utility vs. placebo (estimated treatment difference 0.03; 95% CI 0.01-0.06; nominal p = 0.0015), with consistent effects across fibrosis stages.”
> “This study was sponsored by Novo Nordisk.”

Source: [Augusto et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13651485/)

<a id="topic-4.1-36"></a>

#### Health-state utility weights: SF-6D in noncirrhotic and cirrhotic NAFLD

> “SF-6D 0.660±0.107 in non-cirrhotic NAFLD vs 0.551±0.138 in cirrhotic NAFLD (p=0.0003).”

Source: [Sayiner et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5013331/)

<a id="topic-4.1-37"></a>

#### Lanifibranor: Inventiva statements on coverage, reimbursement, and cost-effectiveness data

> “Market acceptance and sales of lanifibranor, if approved, in both domestic and international markets will depend significantly on the availability of coverage and adequate reimbursement from third-party payors for lanifibranor and may be affected by existing and future healthcare reform measures.”
> “To obtain coverage and reimbursement for any drug that might be approved for sale, we may need to conduct expensive pharmacoeconomic studies to demonstrate the medical necessity and cost-effectiveness of our drug.”

Source: [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm)

<a id="topic-4.1-38"></a>

#### Lanifibranor price, cost-effectiveness analysis, or budget impact analysis

No evidence found.

<a id="heading-4.2"></a>

### 4.2 Budget Impact Model

<a id="heading-4.2.1"></a>

#### 4.2.1 Approach and Framework

No evidence found.

<a id="heading-4.2.2"></a>

#### 4.2.2 Perspective and Time Frame

No evidence found.

<a id="heading-4.2.3"></a>

#### 4.2.3 Epidemiology and Eligible Population Inputs

No evidence found.

<a id="heading-4.2.4"></a>

#### 4.2.4 Cost Assumptions

No evidence found.

<a id="heading-4.2.5"></a>

#### 4.2.5 Model Outcomes

No evidence found.

<a id="heading-4.2.6"></a>

#### 4.2.6 Results

<a id="heading-4.2.6.1"></a>

##### 4.2.6.1 Base Case

No evidence found.

<a id="heading-4.2.6.2"></a>

##### 4.2.6.2 Scenario Analyses

No evidence found.

<a id="heading-4.2.7"></a>

#### 4.2.7 Budget impact model discussion

No evidence found.

## Related pages
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Terms and abbreviations](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations.md)
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Product information and disease description](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Clinical evidence](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: References](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references.md)
